CN1299619A - Protein beverage with the function of reducing cholesterol - Google Patents
Protein beverage with the function of reducing cholesterol Download PDFInfo
- Publication number
- CN1299619A CN1299619A CN 00130861 CN00130861A CN1299619A CN 1299619 A CN1299619 A CN 1299619A CN 00130861 CN00130861 CN 00130861 CN 00130861 A CN00130861 A CN 00130861A CN 1299619 A CN1299619 A CN 1299619A
- Authority
- CN
- China
- Prior art keywords
- phytosterol
- protein beverage
- effect
- beverage
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 83
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 31
- 235000021568 protein beverage Nutrition 0.000 title claims abstract description 26
- -1 aliphatic ester Chemical class 0.000 claims abstract description 42
- 239000002253 acid Substances 0.000 claims abstract description 18
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 11
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims abstract description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims abstract description 7
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims abstract description 7
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims abstract description 7
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims abstract description 7
- 235000000431 campesterol Nutrition 0.000 claims abstract description 7
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 7
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims abstract description 7
- 235000016831 stigmasterol Nutrition 0.000 claims abstract description 7
- 229940032091 stigmasterol Drugs 0.000 claims abstract description 7
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930182558 Sterol Natural products 0.000 claims abstract description 3
- 230000032050 esterification Effects 0.000 claims abstract description 3
- 238000005886 esterification reaction Methods 0.000 claims abstract description 3
- 150000003432 sterols Chemical class 0.000 claims abstract description 3
- 235000003702 sterols Nutrition 0.000 claims abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 38
- 229930195729 fatty acid Natural products 0.000 claims description 38
- 239000000194 fatty acid Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 28
- 235000013361 beverage Nutrition 0.000 claims description 10
- 235000013322 soy milk Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000002270 dispersing agent Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 235000020265 peanut milk Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 3
- 244000299461 Theobroma cacao Species 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000000199 molecular distillation Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 229940076810 beta sitosterol Drugs 0.000 abstract 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 abstract 1
- 229950005143 sitosterol Drugs 0.000 abstract 1
- 108010073771 Soybean Proteins Proteins 0.000 description 13
- 235000019710 soybean protein Nutrition 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000021120 animal protein Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The protein beverage for reducing serum cholesterol comprises 0.1-10% (wt%) of phytosterol aliphatic ester which is made up by phtosterol and aliphatic acid through the process of esterification, in which the phytosterol is the mixture of beta-sitosterol, campesterol, stigmasterol and other natural sterol, and its aliphatic acid is one of C2-C22 aliphatic acids or their mixed aliphatic acid. The protein beverage containing above 0.75g of phytosterol aliphatic ester can be taken in by adult to attain the goal of reducing cholesterol to reduce incidence rate and death rate of coronary heart disease.
Description
The present invention relates to a kind of beverage, specifically relate to a kind of protein beverage that reduces the cholesterol effect that has.
In many countries, the angiocardiopathy death rate accounts for the front three of all disease death rates, accounts for 30～50% of death rate sum.Angiocardiopathy is ratio in the dead sum of China, by rising to till now more than 50% 20% of the fifties.Coronary heart disease is disease common, the most serious in the angiocardiopathy, and the death rate is also the highest.Scientific experimentation shows, and elevated cholesterol and high LDL (low-density lipoprotein) cholesterol are to cause the hazards of coronary heart disease.Scientific research also shows to have only the intervention by extreme harshness, particularly reduces smoking capacity and reduces the high plasma cholesterol level conscientiously by the meals adjustment, and the death rate of coronary heart disease just has significant reduction.
The purpose of this invention is to provide a kind of protein beverage that reduces the serum cholesterol effect that has, can effectively reduce the high plasma cholesterol level after drinking this beverage, thereby reduce the incidence and the death rate of coronary heart disease.
For reaching above-mentioned purpose, the technical solution used in the present invention is: the phytosterol fatty acid ester that adds 0.1～10% (weight) in protein beverage.Described phytosterol fatty acid ester is to be made by esterification by phytosterol and aliphatic acid, and wherein phytosterol is the mixture of cupreol, campesterol, stigmasterol and other natural sterol; Aliphatic acid is C
2～C
22One or more fatty acid mixeds in the aliphatic acid.It can be a kind of liquid beverage that the present invention has the protein beverage that reduces the cholesterol effect, as soymilk, milky cocoa, peanut milk, milk or their mixture, also can be a kind of solid beverage, as soymilk powder, milk powder or their mixture.Because the phytosterol fatty acid ester is that oil soluble material is water insoluble, therefore need it be distributed in the various protein beverages with suitable dispersant.These dispersants can be molecular distillation monoglyceride, sucrose fatty ester, polyglyceryl fatty acid ester, and one or more mixtures in the arm protein acid sodium also can adopt other edible dispersant.Because aliphatic acid mainly is unrighted acid in this phytosterol fatty acid ester, therefore, adding suitable antioxidant in protein beverage needs, as adds a certain amount of vitamin C or vitamin E.
Mechanism of the present invention and characteristics: phytosterol is the solvent of all plants, and their functions in plant are equivalent to the effect of cholesterol in the mammal.The abundantest phytosterol is cupreol, campesterol and stigmasterol in the plant.The structure of these phytosterols and cholesterol are extremely similar, and they only there are differences on the side chain of molecular skeleton.From nineteen fifties, people had recognized already that phytosterol had the effect that reduces serum cholesterol level.Even when using than low dosage number every day gram, they also can effectively reduce the absorbability of biliary cholesterol and dietary cholesterol exposure, thereby reduce total and LDL cholesterol level in the serum.People still not really understand for the restricted cholesterol absorption mechanism, but according to inferring, phytosterol is replaced out the cholesterol in the micellar phase, thereby has stoped being absorbed of cholesterol.Phytosterol has been considered to reduce the safe material of serum cholesterol concentration, and this gives the credit to them is natural constituents of plant fat and vegetable oil.Phytosterol can be easily from edible vegetable oil, goes out in thing or the paper industry tall oil to extract as the deodorization gold-plating of soybean oil, vegetable seed wet goods, all has suitability for industrialized production at present.The phytosterol fatty acid ester is a kind of fatty acid ester blends that phytosterol and aliphatic acid form by chemical reaction.Nearest studies show that, compares with free phytosterol, and the phytosterin ester of aliphatic acid form can more effectively reduce serum cholesterol level.What deserves to be mentioned is that the phytostanol fatty acid ester is different from phytosterol fatty acid ester of the present invention.Phytostanol is that phytosterol makes by catalytic hydrogenation.Make catalyst owing to need to use precious metal palladium, the production cost of phytostanol fatty acid ester will be higher than the phytosterol fatty acid ester, and clinical testing shows, per day for adults be as long as taking in the above phytosterol fatty acid ester of 1.3g can reach and reduce the cholesterol purpose, and if absorption be that the phytostanol fatty acid ester just needs 3.4g.
The phytosterol fatty acid ester is used the existing report of patent in food.As United States Patent (USP) 3,751,569 have described the method for just enjoying interpolation phytosterol fatty acid ester in the oil of preparing food.The purpose of this method is the cholesterol levels that reduces in the human serum.United States Patent (USP) 5,270,041 has described the method that the phytosterol fatty acid ester is applied to oncotherapy, and this patent is referred to above-mentioned substance simultaneously may be as the purposes of diet and food additives, but the data of any relevant serum cholesterol reduction effect are not provided.In fact, all about the application patent and the actual food that all only limits to be rich in fat that uses of phytosterol fatty acid ester, as margarine, vegetable oil.The phytosterol fatty acid ester is applied to the various beverages that are rich in high protein not to be reported as yet.The food that is rich in animal protein contains a certain amount of cholesterol and saturated fat usually, therefore, takes in a large amount of animal proteins for a long time, causes that easily cholesterol levels raises.And on the other hand, vegetable protein such as soybean protein have the effect of the serum cholesterol of reduction, but this effect is a prerequisite to take in the 25g soybean protein every day.In fact, common eating habit all can not guarantee can take in the protein of this quantity every day.The every 100ml of soymilk on the market is soybean protein-containing 2～3g only.If per day for adults can only take in the 15g soybean protein at most, and this is far from reaching above-mentioned dosage requirement to drink 500ml.Therefore, in all kinds of protein beverages, add the phytosterol fatty acid ester, except can solving the cholesterol rising problem that animal protein itself causes, but the also norcholesterol effect of fortification of plants albumen.The present invention finds that first phytosterol fatty acid ester and soybean protein are having good synergy aspect the reduction serum cholesterol, be that to take in 0.75g phytosterol fatty acid ester and 10g soybean protein every day be suitable with taking in the 1.3g phytosterol in the effect that reduces serum total cholesterol level, and take in 0.75g phytosterol fatty acid ester separately or the 10g soybean protein does not all have tangible norcholesterol effect.
Describe the present invention in detail below in conjunction with embodiment.
Embodiment 1
A kind of soymilk formulations with the effect of reduction cholesterol is:
Extract of soybean 8g (wherein soybean protein-containing 3.3g)
White sugar 6g
Soybean oil 2g
Phytosterol fatty acid ester 0.3g
Monoglyceride 0.2g
Sodium Caseinate 0.3g
Sucrose ester (HLB11) 0.2g
V
EIn right amount
Water is made into 100ml
Wherein, adopt the quality index of phytosterol fatty acid ester to be:
Phytosterol fatty acid ester content (weight): 96%
Phytosterol mainly forms and content (weight) is: cupreol 50%, campesterol 28%, stigmasterol 18%
Aliphatic acid is formed and content (weight) is: C
16: 0 6.5%, C
18: 0 5.1%, C
18: 1 65.1%, C
18: 2 22.7%
Embodiment 2
A kind of peanut milk (solid beverage) prescription with the effect of reduction cholesterol is:
Peanut extract 30g
Milk powder 30g
White sugar 25g
Microcapsules phytosterol fatty acid ester 15g
V
E, VC is an amount of
Essence is an amount of
Wherein, adopt the quality index of phytosterol fatty acid ester to be:
Phytosterol fatty acid ester content (weight): 40%
Phytosterol mainly forms and content (weight) is: cupreol 50%, campesterol 28%, stigmasterol 18%
Aliphatic acid is formed and content (weight) is: C
16: 0 6.5%, C
18: 0 5.1%, C
18: 1 65.1%, C
18: 2 22.7%
Embodiment 3
A kind of milk formulas with the effect of reduction cholesterol is:
Milk powder 12g
Monoglyceride 0.1g
Sucrose ester 0.1g
Phytosterol fatty acid ester 0.45g
V
EIn right amount
Water is made into 100ml
Wherein, adopt the quality index of phytosterol fatty acid ester to be:
Phytosterol mainly forms and content (weight) is: cupreol 50%, campesterol 28%, stigmasterol 18%
Aliphatic acid is formed and content (weight) is: C
16: 0 6.5%, C
18: 0 5.1%, C
18: 1 65.1%, C
18: 2 22.7%
Application Example 1
The test group material is selected from the soymilk that makes by embodiment 1 method, drinks 300ml for each person every day, is equivalent to take in every day 0.75g phytosterol fatty acid ester and 10g soybean protein.Control group 1 is taken in the common soymilk of 300ml for each person every day, promptly takes in about 10g soybean protein every day, and control group is taken in 1.3g phytosterol (capsule form) 2 every days.(T-CHOL is taken in 300ml soymilk average 6.01 ± 0.14mmol/L) every days, and edible is at random for 36 aspirations and the healthy women of free living.After taking for 5 weeks, measure serum total cholesterol content.
Table 1 take 5 week back total cholesterol density of serum (mmol/L, n:12)
| Control group 1 | Control group 2 | Test group | |
| T-CHOL | ????6.21±0.16 | ????5.64±0.13 * | ????5.61±0.17 * |
*P＜0.05
Table 1 data show, test group is taken in 0.75g phytosterol and 10g soybean protein every day and taken in 1.3g phytosterol (control group 2) separately and for reducing serum total cholesterol level statistical significance is arranged all.(P＜0.05), and both effects are suitable.Do not reduce the cholesterol effect and take in 10g soybean protein (control group 1) separately.This explanation, phytosterol fatty acid ester and soybean protein are having synergy aspect the reduction serum cholesterol level.In soymilk, add the phytosterol fatty acid ester,, equally also can obtain satisfied reduction cholesterol effect even reduce the phytosterol consumption.
Claims (10)
1, a kind of protein beverage with the effect of reduction cholesterol is characterized in that containing in this protein beverage 0.1～10% (weight) phytosterol fatty acid ester.
2, the protein beverage with the effect of reduction cholesterol as claimed in claim 1 is characterized in that described phytosterol fatty acid ester is to be made by esterification by phytosterol and aliphatic acid.
3, the protein beverage with the effect of reduction cholesterol as claimed in claim 2 is characterized in that described phytosterol is the mixture of cupreol, campesterol, stigmasterol and other natural sterol.
4, the protein beverage with the effect of reduction cholesterol as claimed in claim 2 is characterized in that described aliphatic acid is C
2～C
22One or more fatty acid mixeds in the aliphatic acid.
5, as each described protein beverage with the effect of reduction cholesterol of claim 1～4, it is characterized in that this protein beverage is a kind of liquid beverage, described liquid beverage is soymilk, milky cocoa, peanut milk, milk or their mixture.
6, as each described protein beverage with the effect of reduction cholesterol of claim 1～4, it is characterized in that this protein beverage is a kind of solid beverage, described solid beverage is soymilk powder, cocoa milk powder, peanut milk powder, milk powder or their mixture.
7, the protein beverage with the effect of reduction cholesterol as claimed in claim 1 is characterized in that containing dispersant in this protein beverage.
8, as claimed in claim 7 have a protein beverage that reduces the cholesterol effect, it is characterized in that described dispersant is one or more the mixture in molecular distillation monoglyceride, sucrose fatty ester, polyglyceryl fatty acid ester or the arm protein acid sodium.
9, the protein beverage with the effect of reduction cholesterol as claimed in claim 1 is characterized in that containing antioxidant in this protein beverage.
10, the protein beverage with the effect of reduction cholesterol as claimed in claim 1 is characterized in that described antioxidant is vitamin C or vitamin E.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00130861 CN1299619A (en) | 2000-12-18 | 2000-12-18 | Protein beverage with the function of reducing cholesterol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00130861 CN1299619A (en) | 2000-12-18 | 2000-12-18 | Protein beverage with the function of reducing cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1299619A true CN1299619A (en) | 2001-06-20 |
Family
ID=4594365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00130861 Pending CN1299619A (en) | 2000-12-18 | 2000-12-18 | Protein beverage with the function of reducing cholesterol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1299619A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101248876B (en) * | 2008-03-20 | 2011-08-31 | 杭州娃哈哈集团有限公司 | Norcholesterol health care drink |
| CN102271536A (en) * | 2009-01-26 | 2011-12-07 | 拉伊西奥营养有限公司 | Serum Cholesterol Lowering Beverages |
| CN103393072A (en) * | 2005-11-23 | 2013-11-20 | 可口可乐公司 | High-potency sweetener composition with phytosterol and composition sweetened therewith |
| CN103393063A (en) * | 2005-11-23 | 2013-11-20 | 可口可乐公司 | Natural high-potency sweetener composition with improved temporal profile and/or flavor profile, method for formulation, and uses |
| CN101795580B (en) * | 2007-07-25 | 2014-09-24 | 拉伊西奥营养有限公司 | Beverage and method for its preparation |
| WO2015124083A1 (en) * | 2014-02-24 | 2015-08-27 | 郑鉴忠 | Beverage dissolved with phytosterol and production method therefor |
| US9179690B2 (en) | 2003-04-22 | 2015-11-10 | Raisio Nutrition Ltd. | Edible product with masked bitter, sour and/or astringent taste |
| CN105432793A (en) * | 2010-02-06 | 2016-03-30 | 考格尼斯知识产权管理有限责任公司 | Drink |
-
2000
- 2000-12-18 CN CN 00130861 patent/CN1299619A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9179690B2 (en) | 2003-04-22 | 2015-11-10 | Raisio Nutrition Ltd. | Edible product with masked bitter, sour and/or astringent taste |
| CN103393072A (en) * | 2005-11-23 | 2013-11-20 | 可口可乐公司 | High-potency sweetener composition with phytosterol and composition sweetened therewith |
| CN103393063A (en) * | 2005-11-23 | 2013-11-20 | 可口可乐公司 | Natural high-potency sweetener composition with improved temporal profile and/or flavor profile, method for formulation, and uses |
| CN103393071A (en) * | 2005-11-23 | 2013-11-20 | 可口可乐公司 | High-potency sweetener composition with phytosterol and compositions sweetened therewith |
| CN101795580B (en) * | 2007-07-25 | 2014-09-24 | 拉伊西奥营养有限公司 | Beverage and method for its preparation |
| CN101248876B (en) * | 2008-03-20 | 2011-08-31 | 杭州娃哈哈集团有限公司 | Norcholesterol health care drink |
| CN102271536A (en) * | 2009-01-26 | 2011-12-07 | 拉伊西奥营养有限公司 | Serum Cholesterol Lowering Beverages |
| US9295267B2 (en) | 2009-01-26 | 2016-03-29 | Raisio Nutrition Ltd | Beverage lowering serum cholesterol |
| CN105432793A (en) * | 2010-02-06 | 2016-03-30 | 考格尼斯知识产权管理有限责任公司 | Drink |
| WO2015124083A1 (en) * | 2014-02-24 | 2015-08-27 | 郑鉴忠 | Beverage dissolved with phytosterol and production method therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101268206B1 (en) | Food Products for Diabetics | |
| Takyi | Children′ s consumption of dark green, leafy vegetables with added fat enhances serum retinol | |
| US7090886B2 (en) | Oil/fat composition | |
| EP1307108B1 (en) | Oil/fat composition | |
| CA2417971C (en) | Oil/fat composition | |
| EP2247201B1 (en) | Food products containing omega-3 fatty acids | |
| US20030072858A1 (en) | Oil composition | |
| US6277431B1 (en) | Anticholesterolemic edible oil | |
| AU2005269506A1 (en) | Nutritional compositions and methods for treating or preventing osteoporosis | |
| Bordoni et al. | The role of bioactives in energy metabolism and metabolic syndrome | |
| Baptista et al. | Biological activities of acai (Euterpe oleracea Mart.) and jucara (Euterpe edulis Mart.) intake in humans: An integrative review of clinical trials | |
| US20090053340A1 (en) | Therapeutic uses of tomato extracts | |
| CN1299619A (en) | Protein beverage with the function of reducing cholesterol | |
| US20120156185A1 (en) | Nutritional compositions comprising citrus fibers | |
| WO2007039040A1 (en) | Food composition | |
| EP1370148A1 (en) | Anticholesterolemic edible oil | |
| EP1144458A1 (en) | Substance for reduction of cholesterol as well as lipids content | |
| US20020192318A1 (en) | Anticholesterolemic edible oil | |
| WO2002062329A1 (en) | Therapeutical and nutritional compositions containing pyruvic acid amd glutamine, having antioxidizing activity and capable of controlling overweight | |
| EA026141B1 (en) | Instant functional food product | |
| US6506420B2 (en) | Combinations of psyllium and chitosan for synergistic adsorption of triglyceride | |
| RU2400107C1 (en) | Dietary supplement | |
| RU2220615C1 (en) | Biologically active product | |
| JPWO2005082390A1 (en) | Fat accumulation inhibitor | |
| AU2020263748A1 (en) | GLP-1 secretion-promoting composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |